Exploring the Applications of CD276 (B7-H3)-Targeting Functional Antibodies in Tumor Research

1. Concept

CD276, commonly referred to as B7-H3, is a key member of the B7 family of immune co-regulatory molecules. Classified as a type I transmembrane glycoprotein, it features extracellular immunoglobulin variable-like (IgV) and constant-like (IgC) domains, a transmembrane region, and a short cytoplasmic tail. The 4Ig-B7-H3 isoform—containing two pairs of IgV-IgC domains—is the predominant form in human tissues. Under physiological conditions, B7-H3 expression is restricted to specific cell types in select tissues. However, it is aberrantly overexpressed in a wide range of malignancies, including non-small cell lung cancer, colorectal cancer, breast cancer, pancreatic cancer, and prostate cancer. This abnormal expression correlates strongly with tumor progression, metastatic potential, and poor patient prognosis, establishing B7-H3 as a prominent tumor-associated antigen and a promising immune checkpoint target. Functional antibodies targeting CD276 have emerged as versatile tools in tumor research, enabling the exploration of its biological roles and the development of novel therapeutic strategies.

2. Research Frontiers

2.1 The Multifaceted Roles of B7-H3 in Tumor Biology

B7-H3 exerts complex and critical effects in the tumor microenvironment, encompassing both immune regulatory and non-immune-dependent pro-tumor functions:

• Immune regulatory functions: B7-H3 primarily acts as an immunosuppressive molecule. It inhibits T cell activation and proliferation, impairs the anti-tumor activity of cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and reduces the secretion of key cytokines such as interferon-gamma (IFN-γ). These effects facilitate tumor immune evasion, allowing cancer cells to escape immune surveillance.
• Non-immune-dependent pro-tumor functions: Beyond immune modulation, B7-H3 directly promotes tumor progression through multiple mechanisms:
• Stimulates tumor cell proliferation, epithelial-mesenchymal transition (EMT), invasion, and metastasis via activating signaling pathways like PI3K/AKT and Wnt/β-catenin.
• Induces resistance to chemotherapy (e.g., paclitaxel) and radiotherapy by regulating survival and DNA damage repair pathways such as JAK2/STAT3 and ERK1/2.
• Promotes aerobic glycolysis (Warburg effect) by upregulating key glycolytic enzymes (e.g., hexokinase 2 [HK2]) in tumor cells, supporting rapid growth through enhanced glucose metabolism.
• Enhances tumor angiogenesis by inducing the expression of pro-angiogenic factors like vascular endothelial growth factor (VEGF).

2.2 The Research Value of CD276-Targeting Functional Antibodies

Given B7-H3’s widespread overexpression and multifaceted pro-tumor roles, functional antibodies targeting this molecule are indispensable in basic and translational tumor research:

• Mechanistic research tools: Specific anti-B7-H3 functional antibodies enable precise dissection of its biological mechanisms. By blocking, activating, or crosslinking B7-H3, researchers can investigate its roles in immune suppression, signal transduction, metabolic reprogramming, and therapy resistance in cellular and animal models. For example, antibodies are used to interfere with B7-H3 and observe changes in glycolysis-related molecules (e.g., HK2, LDHA) to validate its metabolic regulatory functions.
• Therapeutic development cornerstones: Anti-B7-H3 antibodies themselves represent promising therapeutic candidates, with multiple strategies under active development:
• Naked antibodies: Exert anti-tumor effects by blocking immunosuppressive signals or mediating antibody-dependent cell-mediated cytotoxicity (ADCC).
• Antibody-drug conjugates (ADCs): Link antibodies to cytotoxic agents for targeted delivery to B7-H3-overexpressing tumor cells, enabling precise tumor killing.
• Bispecific antibodies: Simultaneously target B7-H3 and T cell surface antigens (e.g., CD3), recruiting T cells to tumor sites and activating anti-tumor immunity.
• Immune cell engagers: Provide targeting guidance for adoptive cell therapies such as chimeric antigen receptor T cells (CAR-T).

2.3 Application of Anti-B7-H3 Antibodies in Studying Tumor Glycolysis

Investigating B7-H3’s role in regulating tumor glycolysis is a current research hotspot, relying heavily on functional antibodies and glycolysis-focused tools:

• Expression and co-localization analysis: Anti-B7-H3 antibodies are used in immunohistochemistry, immunofluorescence, or flow cytometry to confirm high B7-H3 expression in tumor models. Combined with antibodies against key glycolytic enzymes (e.g., HK2, PKM2, GLUT1), they enable multiplex staining to analyze spatial co-localization and correlation between B7-H3 and metabolic enzymes, providing preliminary evidence of functional association.
• Functional intervention and phenotype validation: Tumor cells are treated with anti-B7-H3 blocking antibodies or modified via antibody-mediated knockdown/knockout. Glycolysis antibody panels are then used to detect changes in key enzyme levels, while extracellular flux analysis validates alterations in glycolytic flux (e.g., glucose consumption, lactate production) upon B7-H3 inhibition.
• Signaling pathway integration: B7-H3 influences glycolytic gene expression via upstream pathways (e.g., PI3K/AKT/mTOR, HIF-1α). After antibody-mediated B7-H3 intervention, Western blot analysis using antibodies against phosphorylated pathway proteins and glycolytic enzymes constructs a complete signaling axis from B7-H3 to metabolic regulation.

3. Research Significance

Exploring CD276 (B7-H3) and its targeting functional antibodies holds profound significance for tumor research and therapy:

• Basic research value: Elucidates the complex biological roles of B7-H3 in immune evasion, metabolic reprogramming, and therapy resistance, enhancing understanding of tumor progression mechanisms. This knowledge expands the landscape of tumor biology and identifies novel regulatory networks.
• Translational research value: Validates B7-H3 as a promising therapeutic target for multiple malignancies. Functional antibodies targeting B7-H3 not only accelerate preclinical research but also serve as the foundation for developing innovative therapies (e.g., ADCs, bispecific antibodies) that address unmet clinical needs, particularly in patients with refractory or metastatic cancers.

4. Related Mechanisms, Research Methods, and Product Applications

4.1 Core Mechanisms of B7-H3-Mediated Tumor Progression

B7-H3 drives tumor development through interconnected signaling and metabolic pathways:

• Immune suppression: Binds to its unknown receptor on immune cells, inhibiting T/NK cell function and cytokine secretion to promote immune evasion.
• Proliferation and metastasis: Activates PI3K/AKT and Wnt/β-catenin pathways, inducing EMT and enhancing tumor cell motility and invasiveness.
• Metabolic reprogramming: Upregulates glycolytic enzymes via HIF-1α or PI3K/AKT/mTOR signaling, shifting tumor metabolism toward aerobic glycolysis.
• Therapy resistance: Modulates JAK2/STAT3 and ERK1/2 pathways to enhance DNA damage repair and cell survival under chemo/radiotherapy stress.

4.2 Key Research Methods

Studying B7-H3’s roles and antibody applications integrates diverse experimental approaches:

• Expression analysis: Immunohistochemistry, immunofluorescence, and flow cytometry using anti-B7-H3 antibodies to quantify and localize B7-H3 in tumor tissues and cells.
• Functional intervention: Using blocking antibodies to inhibit B7-H3 activity, or activating/crosslinking antibodies to explore gain-of-function effects in vitro and in vivo.
• Metabolic assays: Combining antibody-mediated B7-H3 modulation with extracellular flux analysis and glycolytic enzyme detection to study metabolic changes.
• Signaling pathway analysis: Western blot or immunoprecipitation to investigate B7-H3-mediated activation of downstream pathways (e.g., PI3K/AKT, JAK2/STAT3).
• Preclinical efficacy evaluation: Testing anti-B7-H3 antibodies (alone or in combination with other therapies) in mouse tumor models to assess tumor growth inhibition and immune modulation.

4.3 Product Applications: ANT BIO PTE. LTD.’s CD276-Targeting Functional Antibody

ANT BIO PTE. LTD.’s STARTER brand offers the “Invivo Rat anti-Mouse CD276 Recombinant Monoclonal Antibody (Catalog No.: S0B1361)”—a high-performance tool designed for in vivo functional studies of mouse CD276 (B7-H3). Produced via recombinant technology, this antibody exhibits high specificity and potent blocking activity, enabling precise targeting of mouse B7-H3.

Core Product Advantages

• Definitive in vivo blocking activity: Validated to effectively inhibit the interaction between mouse CD276 and its receptor, supporting studies on immune regulation and tumor progression in animal models.
• Optimized for in vivo safety and purity: Manufactured using a low-endotoxin process (endotoxin <1.0 EU/mg) with sterility testing, minimizing nonspecific immune reactions and ensuring reliable in vivo results.
• Batch consistency: Recombinant production and stringent quality control ensure stable affinity and bioactivity across batches, facilitating reproducible long-term research.

Key Application Areas

• Tumor immunotherapy research: Evaluating the efficacy of CD276 blockade in syngeneic or genetically engineered mouse tumor models, alone or in combination with anti-PD-1/anti-CTLA-4 antibodies.
• Autoimmune and inflammation studies: Investigating CD276’s regulatory role in experimental autoimmune encephalomyelitis (EAE), collagen-induced arthritis (CIA), and other inflammatory models.
• Transplantation immunology: Exploring CD276’s role in organ transplant rejection or graft-versus-host disease (GVHD) and assessing its potential as an intervention target.
• Immune cell function analysis: Elucidating CD276’s effects on T cell, NK cell, and myeloid cell activation, differentiation, and function in vivo.

ANT BIO PTE. LTD. provides comprehensive technical support, including quality analysis reports (purity, concentration, endotoxin levels, bioactivity), recommended in vivo dosing protocols, and expert consultation for experimental design.

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to empowering the global life science community with high-quality, innovative research tools and solutions. As a leader in life science reagents, we offer a comprehensive portfolio under three sub-brands: Absin (focused on general reagents and kits), Starter (specialized in antibodies), and UA (dedicated to recombinant proteins).

Our commitment to excellence is underpinned by advanced development platforms—including recombinant rabbit/mouse monoclonal antibody platforms, rapid monoclonal antibody development, recombinant protein expression systems (E. coli, CHO, HEK293, Insect Cells), One-Step ELISA Platforms, and PTM Pan-Modification Antibody Platforms—alongside rigorous quality control systems. We hold international certifications such as EU 98/79/EC, ISO9001, and ISO13485, ensuring our products meet the highest global standards.

Our mission is to accelerate scientific discovery, facilitate translational research, and contribute to the development of novel therapies for human health. By partnering with researchers in academia and biopharmaceutical companies worldwide, we strive to be a trusted collaborator in advancing life science research and addressing unmet medical needs.

6. Related Product List

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.